A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00134992 |
Recruitment Status :
Completed
First Posted : August 25, 2005
Last Update Posted : June 9, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Prednisolone acetate | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers |
Study Start Date : | August 2004 |

- Tolerability of the trial drug by evaluating the overall sum-score of the slit lamp examination built by adding up the scores for conjunctival hyperemia, conjunctival edema, palpebral hyperemia, lid edema and corneal edema
- Tolerability of the trial drug
- and the frequency, severity and relationship to study medication of all adverse events occurring during the course of the study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy subjects of either gender, 18 years or older, who were able to give an informed consent
- A score for ocular discomfort of 0-20 mm on the visual analogue scale (VAS) prior to treatment
Exclusion Criteria:
- Known hypersensitivity to any of the constituents of the medications
- Known corticosteroid responder (elevation of intraocular pressure [IOP])
- Known allergic disposition (e.g. hay fever)
- Need of ocular antiallergic treatment
- Wearing of contact lenses
- Any kind of current eye disease (e.g. dry eye)
- Any kind of concomitant ocular treatment
- Any injury or infection in either eye during the last 3 months prior to the first application
- Any medication taken within the last 28 days prior to the first application, except hormonal contraceptives
- Concomitant or previous treatment with antihistamines within a week prior to enrolment
- Pregnant or breast feeding women
- Participation in another clinical study within 4 weeks prior to enrolment
- Hematological diseases such as aplastic anemia, panmyelopathy, or hemolytic icterus; with severe dysfunction of the liver.
- Any medical or laboratory condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol
- Subjects with history of malignancy of any organ system, treated or untreated, within the past five years, whether or not evidence of local recurrence or metastases exist, are excluded, with the exception of localized basal cell carcinoma of the skin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134992
Germany | |
Kopfklinik der Ruprechts-Karls- Universität | |
Heidelberg, Germany |
Study Chair: | Novartis Customer Information | Novartis |
ClinicalTrials.gov Identifier: | NCT00134992 |
Other Study ID Numbers: |
CULT 491 DE 02 |
First Posted: | August 25, 2005 Key Record Dates |
Last Update Posted: | June 9, 2006 |
Last Verified: | June 2006 |
Prednisolone acetate eye drops tolerability Healthy volunteers |
Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Glucocorticoids Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |